<DOC>
	<DOCNO>NCT02652130</DOCNO>
	<brief_summary>Ongoing safety assessment follow Protocol MSB-GVHD 001 remestemcel-L treatment pediatric subject acute Graft versus Host Disease ( aGVHD ) , follow allogeneic hematopoietic stem cell transplant ( HSCT ) , fail respond treatment systemic corticosteroid therapy .</brief_summary>
	<brief_title>Safety Follow-up Treatment With Remestemcel-L Pediatric Patients Who Have Failed Respond Steroid Treatment Acute GVHD</brief_title>
	<detailed_description>This safety follow-up study 180 day remestemcel-L treatment subject participate MSB-GVHD001 . This study also explore duration response time . Subjects participate MSB-GVHD001 receive least one dose remestemcel-L outline protocol evaluate baseline ( Day 100 ) Days 120 , 140 , 160 180 safety endpoint . Subjects participate Protocol MSB-GVHD001 receive first 8 dos remestemcel-L outline protocol evaluate baseline ( Day 100 ) Days 120 , 140 , 160 180 .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<criteria>Patients eligible study follow criterion meet : Subjects must participate gvhd001 receive least one infusion remestemcel L Subject subject 's authorized representative must capable provide write informed consent . Assent , applicable , must also collect required Institutional Review Board ( IRB ) /Ethics Committee ( EC ) . Female subject childbearing potential ( â‰¥ 10 year age ) must use medically accept method contraception must agree continue use method duration study followup time period . Acceptable method contraception include abstinence , barrier method spermicide , intrauterine device ( IUD ) , steroidal contraceptive ( oral , transdermal , implanted , inject ) conjunction barrier method . The subject must willing able comply study procedure , remain clinic require study period , return clinic followup evaluation specify protocol . The investigator believe best interest subject participate safety follow study .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>GVHD , Graft versus Host Disease</keyword>
</DOC>